CHIARINI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.312
NA - Nord America 3.255
EU - Europa 1.510
SA - Sud America 612
AF - Africa 36
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.730
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.194
CN - Cina 1.780
SG - Singapore 1.420
BR - Brasile 488
HK - Hong Kong 451
IT - Italia 382
GB - Regno Unito 345
KR - Corea 231
VN - Vietnam 227
SE - Svezia 189
RU - Federazione Russa 163
DE - Germania 121
ID - Indonesia 73
FI - Finlandia 60
LT - Lituania 55
AR - Argentina 54
NL - Olanda 51
IE - Irlanda 30
EC - Ecuador 27
FR - Francia 27
AT - Austria 23
MX - Messico 23
IN - India 21
CA - Canada 20
BD - Bangladesh 17
IQ - Iraq 17
ZA - Sudafrica 16
JP - Giappone 14
PL - Polonia 14
TR - Turchia 12
UA - Ucraina 12
VE - Venezuela 11
CL - Cile 8
PY - Paraguay 7
ES - Italia 6
IL - Israele 6
KE - Kenya 6
PK - Pakistan 6
CO - Colombia 5
CZ - Repubblica Ceca 5
MA - Marocco 5
PA - Panama 5
SA - Arabia Saudita 5
UY - Uruguay 5
AL - Albania 4
DO - Repubblica Dominicana 4
PE - Perù 4
RO - Romania 4
UZ - Uzbekistan 4
AU - Australia 3
BG - Bulgaria 3
BO - Bolivia 3
CR - Costa Rica 3
EG - Egitto 3
LA - Repubblica Popolare Democratica del Laos 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AZ - Azerbaigian 2
GT - Guatemala 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
MD - Moldavia 2
NP - Nepal 2
PH - Filippine 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DZ - Algeria 1
GE - Georgia 1
HN - Honduras 1
IR - Iran 1
IS - Islanda 1
JM - Giamaica 1
KW - Kuwait 1
MN - Mongolia 1
MU - Mauritius 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 9.730
Salva come PNG Salva come JPEG
Città #
Hefei 1.197
Santa Clara 1.042
Singapore 776
Ashburn 502
Hong Kong 449
Dallas 293
Seoul 231
London 215
Nyköping 140
Beijing 106
Los Angeles 100
The Dalles 76
Ho Chi Minh City 70
Kent 70
Chicago 68
Shanghai 68
Hanoi 63
Jakarta 62
Munich 58
Buffalo 54
Fairfield 54
Moscow 52
Chandler 50
Helsinki 39
Houston 39
São Paulo 38
Milan 36
Bologna 34
New York 33
Woodbridge 32
Dublin 30
Southend 30
Parma 29
Redondo Beach 24
Tampa 23
Rome 22
Salt Lake City 22
Modena 21
Amsterdam 20
Nuremberg 20
Cambridge 19
Seattle 18
Wilmington 18
Frankfurt am Main 16
Guangzhou 16
Reggio Emilia 16
Brasília 14
Rio de Janeiro 14
Washington 14
Columbus 13
Indianapolis 12
Stockholm 12
Atlanta 11
Belo Horizonte 11
Kilburn 11
Lancaster 11
Paris 11
Turku 11
Warsaw 11
Elk Grove Village 10
Haiphong 10
Orem 10
Tokyo 10
Baghdad 9
Boston 9
Brooklyn 9
Chiswick 9
Da Nang 9
Lappeenranta 9
Padova 9
Phoenix 9
Poplar 9
Tianjin 9
Vienna 9
Ann Arbor 8
Assago 8
Campinas 8
Curitiba 8
Hillsboro 8
Islington 8
Johannesburg 8
Mexico City 8
Montreal 8
Quito 8
Buenos Aires 7
Jacksonville 7
Salvador 7
San Diego 7
Sterling 7
Thái Bình 7
Torre del Greco 7
Wuhan 7
Changsha 6
Chennai 6
Glasgow 6
Guayaquil 6
Hounslow 6
Porto Alegre 6
Ribeirão Preto 6
Carpi 5
Totale 6.869
Salva come PNG Salva come JPEG
Nome #
Dual inhibition of PI3K/mTOR signaling in chemoresistant AMLprimary cells. 282
Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance 210
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer 209
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 193
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: Turning offthe prosurvival ER chaperone BIP/Grp78 and turning on the proapoptotic NF-κB 190
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 142
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? 142
Molecular Signature of Biological Aggressiveness in Clear Cell Sarcoma of the Kidney (CCSK) 137
Assessment of the structural and functional characteristics of human mesenchymal stem cells associated with a prolonged exposure of morphine 129
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 129
Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model 129
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting 128
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 126
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells 126
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 125
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 124
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 123
A role of PI-PLCb1 in G1/S transition in human erythroleukemia k562 cells 123
Cellular senescence in vascular wall mesenchymal stromal cells, a possible contribution to the development of aortic aneurysm 121
13. PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation 121
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia 118
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 118
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics 118
Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies 118
Targeting metabolic vulnerabilities and aberrant signal transduction pathways in paediatric T-cell Acute Lymphoblastic Leukaemia (T-ALL) 118
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications 116
Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a 116
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 113
Involvement of nuclear PLC{beta}1 in lamin B1 phosphorylation and G2/M cell cycle progression 112
Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells 110
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells 109
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 109
Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia 107
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response 106
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines 105
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 103
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS 101
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 100
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications 100
The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia 99
Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells 99
GSK-3: a multifaceted player in acute leukemias 98
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia 98
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside 97
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia 96
K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway 94
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies 92
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment 92
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway 90
Current treatment strategies for inhibiting mTOR in cancer 89
The Cutting Edge: The Role of mTOR Signaling in Laminopathies 89
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia 89
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 89
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance 88
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels 88
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML 88
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia 88
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia 87
Differential Cytotoxicity of Surface-Functionalized Silver Nanoparticles in Colorectal Cancer and Ex-Vivo Healthy Colonocyte Models 86
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 86
Therapeutic targeting of CK2 in acute and chronic leukemias 85
Implication of Cellular Senescence in Osteoarthritis: A Study on Equine Synovial Fluid Mesenchymal Stromal Cells 85
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients 84
The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine 84
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 84
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 83
Targeting the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in acute myelogenous leukaemia 82
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) 81
At the Nucleus of Cancer – How the Nuclear Envelope Controls Tumor Progression 80
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage 80
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 79
Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias 79
Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells 78
Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients 78
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors 78
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update 77
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia 77
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 77
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology 75
Surface Charge Overrides Protein Corona Formation in Determining the Cytotoxicity, Cellular Uptake, and Biodistribution of Silver Nanoparticles 72
Magnesium and strontium-enriched bioactive glasses: superior biocompatibility and angiogenesis, beyond the gold standard 72
Dual inhibition of class IA phoshatidylinositol 3-kinase and mTOR as a new therapeutic option for T-cell acute lymphoblastic leukemia 71
Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib 71
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms 70
Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation 70
The unfolded protein response: a novel therapeutic target in acute leukemias 69
Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL) 68
Lamin A acts a tumor suppressor in Ewing sarcoma promoting neural differentiation and reducing cell migration and invasion 67
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 67
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia 65
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 64
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy 63
C033 Quantification of phosphoinositidephospholipase C (PI-PLC) beta 1 gene promoter methylation predicts the responsiveness to azacitidine in myelodysplastic syndromes 61
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 61
C025 Role of lipid signaling pathways in the response to erythropoietin in low risk MDS patients 59
The emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in normal myelopoieis and leukemogenesis 58
New agents and approaches for targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cell survival pathways 39
Development and 3D Printing of AESO-Based Composites Containing Olive Pit Powder 38
Advances in Targeting Signal Transduction Pathways 6
The Association Between Muscle Strength, Body Cell Mass, and Training Session Hours in Young Female Artistic Gymnasts: A Pilot Study 3
Totale 9.768
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.930
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.930
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202190 0 0 0 0 0 19 12 15 10 7 14 13
2021/202274 3 6 4 13 2 4 2 6 6 7 13 8
2022/2023514 5 7 11 24 41 66 30 61 94 19 58 98
2023/2024871 35 26 37 145 120 64 173 60 20 28 86 77
2024/20253.810 83 19 13 227 848 625 109 143 385 125 608 625
2025/20264.220 707 634 1.099 876 661 243 0 0 0 0 0 0
Totale 9.768